

# Mark Lythgoe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6679561/publications.pdf>

Version: 2024-02-01

44  
papers

1,118  
citations

516215

16  
h-index

433756

31  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends in Pharmacological Sciences, 2020, 41, 363-382.	4.0	311
2	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	0.8	135
3	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	2.0	70
4	Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	41
5	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	41
6	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39
7	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	38
8	Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. , 2016, 164, 195-203.		37
9	Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Familial Cancer, 2018, 17, 557-564.	0.9	36
10	Gene of the month: lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology, 2021, 74, 543-547.	1.0	35
11	Oncologist-led BRCA "mainstreaming"™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports, 2020, 10, 3390.	1.6	34
12	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.2	32
13	Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada. JAMA Network Open, 2021, 4, e2114531.	2.8	28
14	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. JAMA Network Open, 2022, 5, e2216183.	2.8	27
15	Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterology, 2021, 8, e000739.	1.1	26
16	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Network Open, 2022, 5, e222265.	2.8	26
17	Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. JAMA Network Open, 2021, 4, e2135123.	2.8	20
18	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology. <i>British Journal of Cancer</i> , 2022, 127, 785-787.	2.9	16
20	The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval. <i>JAMA Oncology</i> , 2021, 7, 1607-1609.	3.4	14
21	Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006—2020. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1208-1211.	2.0	11
22	Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 351-361.	0.9	10
23	Good practice in shared care for inflammatory arthritis. <i>British Journal of General Practice</i> , 2016, 66, 275-277.	0.7	9
24	The potential of fecal microbiota transplantation in oncology. <i>Trends in Microbiology</i> , 2022, 30, 10-12.	3.5	9
25	Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019. <i>Drug Discovery Today</i> , 2021, 26, 301-307.	3.2	8
26	How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. <i>European Journal of Cancer</i> , 2021, 157, 68-70.	1.3	7
27	High US drug prices have global implications. <i>BMJ</i> , The, 2022, 376, o693.	3.0	7
28	The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014—2018. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 93-98.	0.5	5
29	Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approval. <i>European Journal of Cancer</i> , 2022, 169, 103-105.	1.3	5
30	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
31	Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. <i>Cancers</i> , 2021, 13, 4232.	1.7	3
32	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
33	Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021. <i>BJU International</i> , 2022, 129, 168-170.	1.3	3
34	Tacrolimus: an effective treatment in refractory psoriatic arthritis following biologic failure. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S12-3.	0.4	3
35	Regorafenib therapy for hepatocellular carcinoma in a HIV-infected patient: A case report. <i>Liver Cancer International</i> , 2020, 1, 51-54.	0.2	2
36	Response to letter to editor regarding published article—metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. <i>Familial Cancer</i> , 2018, 17, 545-546.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Safe administration of chemotherapy in mast cell activation syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1005-1010.	0.5	1
38	The FDA's latest move to expand eligibility for oncology trials – a double-edged sword?. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 745-746.	12.5	1
39	The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. <i>European Journal of Cancer</i> , 2021, 159, 56-59.	1.3	1
40	CostPlus and implications for generic imatinib. <i>The Lancet Regional Health Americas</i> , 2022, 13, 100317.	1.5	1
41	Effective antidotes for new anticoagulants. <i>BMJ</i> , 2015, 350, h2775-h2775.	3.0	0
42	V6, PRIMROSE: A national trainee collaborative-led, multicentre prospective audit on the care of breast cancer patients with central nervous system disease in the UK. <i>BJS Open</i> , 2021, 5, .	0.7	0
43	Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. <i>Cancers</i> , 2021, 13, 4181.	1.7	0
44	The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer. <i>Journal of Cancer Policy</i> , 2022, 31, 100322.	0.6	0